ReviewReviews in endocrine & metabolic disorders2021
Glucocorticoid excess and COVID-19 disease.
Review in Reviews in endocrine & metabolic disorders, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed, 3 syntheses or guidelines pooled it, 55 citations in OpenAlex.
- The pandemic is gone but its consequences are here to stay: avascular necrosis following corticosteroids administration for severe COVID-19.Journal of orthopaedic surgery and research · 2024Pooled it
- Prevalence of hypertension and associated risks in hospitalized patients with COVID-19: a meta-analysis of meta-analyses with 1468 studies and 1,281,510 patients.Systematic reviews · 2022Pooled it
- Corticosteroid use in ARDS and its application to evolving therapeutics for coronavirus disease 2019 (COVID-19): A systematic review.Pharmacotherapy · 2022Pooled it
- Mechanisms of inflammation in premature ovarian insufficiency and advances in therapeutic studies.Frontiers in immunology · 2026Review
- The development of a therapeutic strategy for post-acute sequelae of COVID-19 should be based on an efficient classification of pathogenesis.Frontiers in medicine · 2025Article
- Cushing's syndrome and COVID-19.Pituitary · 2024Review
- The risk of COVID-19 in Cushing's disease is independently related to disease activity (hypercortisolism) and obesity.Archives of endocrinology and metabolism · 2024Article
- A Retrospective Data Audit of Outcome of Moderate and Severe Covid-19 Patients Who Had Received MP and Dex: A Single Center Study.Infection and drug resistance · 2024Article
- The glucocorticoid dose-mortality nexus in pneumonia patients: unveiling the threshold effect.Frontiers in pharmacology · 2024Article
- COVID-19 pandemic and adrenals: deep insights and implications in patients with glucocorticoid disorders.Endocrine · 2023Review
- Pituitary and SARS CoV-2: An unremitting conundrum.Best practice & research. Clinical endocrinology & metabolism · 2023Review
- Evaluation of Possible Association between Serum Levels of Aldosterone and Cortisol with Clinical Symptoms Progression in COVID-19 Suspicious Outpatients Tested for SARS-CoV2 RT-PCR: An Analytical Cross-Sectional Study.Archives of Razi Institute · 2023Article
- Corticosteroids treatment for pediatric acute respiratory syndrome: A critical review.Saudi medical journal · 2023Review
- Susceptibility and characteristics of infections in patients with glucocorticoid excess or insufficiency: the ICARO tool.European journal of endocrinology · 2022Article
- New Insights on Effects of Glucocorticoids in Patients With SARS-CoV-2 Infection.Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists · 2022Review
- Effects of COVID-19 in Endocrine Patients: A Cross-Sectional Study.Medicina (Kaunas, Lithuania) · 2022Article
- The systemic immunosuppressive effects of peripheral corticosteroid injections: A narrative review of the evidence in the context of COVID-19.Musculoskeletal care · 2022Review
- Analysis of post COVID-19 condition and its overlap with myalgic encephalomyelitis/chronic fatigue syndrome.Journal of advanced research · 2022Review
- [Pituitary and COVID-19: review].Problemy endokrinologii · 2022Review
- The Relationship between COVID-19 and Hypothalamic-Pituitary-Adrenal Axis: A Large Spectrum from Glucocorticoid Insufficiency to Excess-The CAPISCO International Expert Panel.International journal of molecular sciences · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 5 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The pandemic of coronavirus disease (COVID-19), a disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is causing high and rapid morbidity and mortality. Immune system response plays a crucial role in controlling and resolving the viral infection. Exogenous or endogenous glucocorticoid excess is characterized by increased susceptibility to infections, due to impairment of the innate and adaptive immune system. In addition, diabetes, hypertension, obesity and thromboembolism are conditions overrepresented in patients with hypercortisolism. Thus patients with chronic glucocorticoid (GC) excess may be at high risk of developing COVID-19 infection with a severe clinical course. Care and control of all comorbidities should be one of the primary goals in patients with hypercortisolism requiring immediate and aggressive treatment. The European Society of Endocrinology (ESE), has recently commissioned an urgent clinical guidance document on management of Cushing's syndrome in a COVID-19 period. In this review, we aim to discuss and expand some clinical points related to GC excess that may have an impact on COVID-19 infection, in terms of both contagion risk and clinical outcome. This document is addressed to all specialists who approach patients with endogenous or exogenous GC excess and COVID-19 infection.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.